Archives

GIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical’s Phase III Results Signal Differentiation in Weight Loss Arena

B SUZHOU, China, May 12, 2026 /PRNewswire/ — As competition in the weight loss drug market progressively intensifies, the latest Phase III clinical data disclosed… Login to continue reading Login…

Read MoreGIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical’s Phase III Results Signal Differentiation in Weight Loss Arena

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

B Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include 13 programs with the… Login to continue reading Login…

Read MoreHengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology